The antagonistic activity of the synbiotic containing Lactobacillus acidophilus and pineapple residue FOS against pathogenic bacteria / A atividade antagônica do simbiótico contendo Lactobacillus acidophilus e resíduo de abacaxi FOS contra bactérias patogênicas

Fructooligosaccharide is used widely in many foods and pharmaceutical industries and produced by using different ways such as extracting it from plants or producing it by using plants and microorganisms' enzymes. In a previous study, we extracted Fructosyltransferase (Ftase) enzyme from pineapple residue and produced FOS. In this study, we measured the antagonistic activity of two synbiotics, the first synbiotic containing Lactobacillus acidophilus and the produced FOS, the second synbiotic containing Lactobacillus acidophilus and standard FOS, against pathogenic bacteria (P. aeruginosa, E. coli, S. aureus and B cereus). The results showed that the antagonistic activity of both synbiotic types was very close, as there were no significant differences between them except in the antagonistic activity against S. aureus, there was a significant difference between the synbiotic containing the standard FOS, which was the highest in its antagonistic activity compared to the synbiotic containing the produced FOS in this study. The activity of the fructooligosaccharide (FOS) extracted from pineapple residue was evident in enhancing the activity of the probiotic bacteria (L. acidophilus), which had a major role in the production of acids and compounds that inhibited the pathogenic bacteria. The diameters of inhibition areas in the current study ranged between 19.33-28 mm, and E. coli was more susceptible to inhibition, followed by S. aureus, P. aeruginosa, and B. cereus, respectively.

O fruto-oligossacarídeo (FOS) é amplamente utilizado em muitos alimentos e indústrias farmacêuticas, e é produzido por meio de diferentes maneiras, como extraí-lo de plantas ou produzi-lo usando enzimas de plantas e microrganismos. Em um estudo anterior, extraímos a enzima frutosiltransferase (Ftase) do resíduo de abacaxi e produzimos FOS. Neste estudo, medimos a atividade antagônica de dois simbióticos: o primeiro simbiótico contendo Lactobacillus acidophilus e o FOS produzido, e o segundo simbiótico contendo Lactobacillus acidophilus e o FOS padrão, contra bactérias patogênicas (P. aeruginosa, E. coli, S. aureus e B. cereus). Os resultados mostraram que a atividade antagônica de ambos os tipos simbióticos foi muito próxima, pois não houve diferenças significativas entre eles, exceto na atividade antagônica contra S. aureus, em que houve uma diferença significativa entre o simbiótico contendo o FOS padrão, que foi o mais alto em sua atividade antagônica, em comparação com o simbiótico contendo o FOS produzido neste estudo. A atividade do fruto-oligossacarídeo (FOS) extraído do resíduo de abacaxi ficou evidente no aumento da atividade da bactéria probiótica (L. acidophilus), que teve papel importante na produção de ácidos e compostos inibidores das bactérias patogênicas. Os diâmetros das áreas de inibição no estudo atual variaram entre 19,33 e 28 mm, e E. coli foi mais suscetível à inibição, seguida por S. aureus, P. aeruginosa e B. cereus, respectivamente.

The antagonistic activity of the synbiotic containing Lactobacillus acidophilus and pineapple residue FOS against pathogenic bacteria

Abstract Fructooligosaccharide is used widely in many foods and pharmaceutical industries and produced by using different ways such as extracting it from plants or producing it by using plants and microorganisms enzymes. In a previous study, we extracted Fructosyltransferase (Ftase) enzyme from pineapple residue and produced FOS. In this study, we measured the antagonistic activity of two synbiotics, the first synbiotic containing Lactobacillus acidophilus and the produced FOS, the second synbiotic containing Lactobacillus acidophilus and standard FOS, against pathogenic bacteria (P. aeruginosa, E. coli, S. aureus and B cereus). The results showed that the antagonistic activity of both synbiotic types was very close, as there were no significant differences between them except in the antagonistic activity against S. aureus, there was a significant difference between the synbiotic containing the standard FOS, which was the highest in its antagonistic activity compared to the synbiotic containing the produced FOS in this study. The activity of the fructooligosaccharide (FOS) extracted from pineapple residue was evident in enhancing the activity of the probiotic bacteria (L. acidophilus), which had a major role in the production of acids and compounds that inhibited the pathogenic bacteria. The diameters of inhibition areas in the current study ranged between 19.33-28 mm, and E. coli was more susceptible to inhibition, followed by S. aureus, P. aeruginosa, and B. cereus, respectively.

Resumo O fruto-oligossacarídeo (FOS) é amplamente utilizado em muitos alimentos e indústrias farmacêuticas, e é produzido por meio de diferentes maneiras, como extraí-lo de plantas ou produzi-lo usando enzimas de plantas e microrganismos. Em um estudo anterior, extraímos a enzima frutosiltransferase (Ftase) do resíduo de abacaxi e produzimos FOS. Neste estudo, medimos a atividade antagônica de dois simbióticos: o primeiro simbiótico contendo Lactobacillus acidophilus e o FOS produzido, e o segundo simbiótico contendo Lactobacillus acidophilus e o FOS padrão, contra bactérias patogênicas (P. aeruginosa, E. coli, S. aureus e B. cereus). Os resultados mostraram que a atividade antagônica de ambos os tipos simbióticos foi muito próxima, pois não houve diferenças significativas entre eles, exceto na atividade antagônica contra S. aureus, em que houve uma diferença significativa entre o simbiótico contendo o FOS padrão, que foi o mais alto em sua atividade antagônica, em comparação com o simbiótico contendo o FOS produzido neste estudo. A atividade do fruto-oligossacarídeo (FOS) extraído do resíduo de abacaxi ficou evidente no aumento da atividade da bactéria probiótica (L. acidophilus), que teve papel importante na produção de ácidos e compostos inibidores das bactérias patogênicas. Os diâmetros das áreas de inibição no estudo atual variaram entre 19,33 e 28 mm, e E. coli foi mais suscetível à inibição, seguida por S. aureus, P. aeruginosa e B. cereus, respectivamente.

Comparative prospective randomized open label trial of synbiotic (bifilac) as an add on therapy with standard treatment in patients with aphthous ulcer

Background: To trial the safety, efficacy and rapidity of response to a lozenges containing synbiotic in patients with minor aphthous ulcer.Methods: A total of 60 patients were enrolled for the trial after obtaining IEC approval and randomly allocated into two groups. Control “Group A” was administered with conventional treatment i.e., zytee and B complex for 2 weeks and trial “Group B” was administered with Bifilac along with conventional treatment for 2 weeks. The results of this trial were analyzed both subjectively and objectively.Results: Comparing with control group, where standard treatment was used with analgesics and B-complex, the trial group showed a quick relief of pain and helped in reducing mean size of ulcer.Conclusions: This trial was done with synbiotic lozenges in minor aphthous ulcers and it proved to be better alternative for them. Moreover, synbiotics have no adverse effects.

A comprehensive review on clinical outcome of probiotic and synbiotic therapy for inflammatory bowel diseases

The composition of gut microflora and its metabolic activity are closely correlated with the host immune system,and the changes in the biometric of the microbiome lead to inflammatory diseases like inflammatory bowel disease.The supplementation of probiotics and synbiotic could indeed manipulate the microflora,which can be an alternative therapy for ulcerative colitis,and Crohn's disease.Several in vitro,in vivo and clinical studies for the initiation and maintenance of remission in patients with inflammatory bowel disease have been completed.Those studies evaluated the efficacy of many probiotic formulations,especially about VSL#3.Even though the clinical studies proved that almost all the probiotic interventions are safe and bring improvement to patients,some studies are deficient in sample size,proper controls,and follow-ups.This paper summarizes the possible mechanism of inflammatory bowel disease development,probiotics,the clinical outcome of probiotic and synbiotic interventions for ulcerative colitis and Crohn's disease,as well as the adverse effect of probiotic treatments.

A comprehensive review on clinical outcome of probiotic and synbiotic therapy for inflammatory bowel diseases

The composition of gut microflora and its metabolic activity are closely correlated with the host immune system, and the changes in the biometric of the microbiome lead to inflammatory diseases like inflammatory bowel disease. The supplementation of probiotics and synbiotic could indeed manipulate the microflora, which can be an alternative therapy for ulcerative colitis, and Crohn's disease. Several in vitro, in vivo and clinical studies for the initiation and maintenance of remission in patients with inflammatory bowel disease have been completed. Those studies evaluated the efficacy of many probiotic formulations, especially about VSL#3. Even though the clinical studies proved that almost all the probiotic interventions are safe and bring improvement to patients, some studies are deficient in sample size, proper controls, and follow-ups. This paper summarizes the possible mechanism of inflammatory bowel disease development, probiotics, the clinical outcome of probiotic and synbiotic interventions for ulcerative colitis and Crohn's disease, as well as the adverse effect of probiotic treatments.

Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease

BACKGROUND/AIMS: Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver diseases in recent years. The aim of this study was to evaluate the effects of sitagliptin with and without a synbiotic supplement in the treatment of patients with NAFLD. METHODS: In total, 138 NAFLD patients aged 18-60 years were enrolled in the study. Patients were randomized to one of the following treatments for 16 weeks: Group I (n=68), sitagliptin 50 mg daily plus placebo (one capsule per day) or group II (n=70) sitagliptin 50 mg daily plus synbiotic (one capsule per day). Changes in fasting blood glucose (FBS), liver enzymes, lipid profile, and body mass index were compared between the groups. RESULTS: The mean change in FBS with sitagliptin-placebo from baseline was -10.47±5.77 mg/dL, and that with sitagliptin-synbiotic was -13.52±4.16 mg/dL. There was a significant difference between the groups (P < 0.001). The mean change in cholesterol (Chol) was -8.34±28.83 mg/dL with sitagliptin-placebo and -21.25±15.50 mg/dL with sitagliptinsynbiotic. There was a significant difference between the two groups (P=0.029). The administration of sitagliptin-placebo induced an increase of 6.13±27.04 mg/dL in low density lipoprotein (LDL), whereas sitagliptin-synbiotic induced a decrease of 14.92±15.85 mg/dL in LDL. A significant difference was observed between the two groups (P < 0.001). On the other hand, in the sitagliptin-synbiotic group, there was significant improvement in aspartate aminotransferase (AST) level compared to the sitagliptin-placebo group (P=0.018). CONCLUSIONS: Sitagliptin-synbiotic produced greater improvement in FBS, AST, Chol, and LDL compared to sitagliptin alone in patients with NAFLD.

Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone?

No abstract available.

Experiencia clínica con un simbiótico (Bifidobacterium longum AW11- Fos cc. Actilight) en el alivio del estreñimiento y otros síntomas digestivos / Clinical experience with a synbiotic (Bifidobacterium longum AW11- Fos cc. Actilight) in the relieve of constipation and other digestive symptoms

Resumen: ANTECEDENTES: el estreñimiento, la distensión y el dolor abdominales son muy prevalentes en la población general y representan un reto terapéutico. Los probióticos han mostrado ser efectivos en el control de estos síntomas. OBJETIVO: investigar la utilidad clínica de la administración del simbiótico Bifidobacterium longum AW11 (5x109 UFC) y fructo-oligosacáridos de cadena corta (Fos cc. Actilight 2.5 g) en el alivio del estreñimiento y otros síntomas digestivos. PACIENTES Y MÉTODO: estudio abierto observacional en el que se incluyeron pacientes con síntomas digestivos de más de seis meses de evolución, sin enfermedad orgánica que explicara sus síntomas y que recibieron tratamiento con el simbiótico, un sobre diario durante ocho semanas. La intensidad y frecuencia de los síntomas se evaluaron mediante un cuestionario y las características de las evacuaciones mediante la escala de Bristol al inicio, a las cuatro y a las ocho semanas de tratamiento. RESULTADOS: se incluyeron 361 pacientes con síntomas digestivos. El promedio de la duración de los síntomas fue de 2.3±4.9 años, 96% tenía estreñimiento, 79% cumplió con criterios de síndrome de intestino irritable y 16% de estreñimiento funcional (Roma III). El número de evacuaciones semanales se incrementó de 3.8±3.3 iniciales a 5.9±3.0 en la semana 8 (p<0.00001). También mejoraron significativamente: el número de evacuaciones espontáneas completas, la consistencia de las heces (escala de Bristol) y la sensación global de bienestar y disminuyeron significativamente el esfuerzo al defecar, la distensión abdominal subjetiva, la frecuencia de dolor abdominal y la sensación de malestar abdominal. La proporción de pacientes totalmente satisfechos se incrementó de 6% al inicio a 78% en la semana 8. CONCLUSIONES: la administración diaria del simbiótico con B. longum y Fos cc. es eficaz para aliviar el estreñimiento y el dolor y la distensión abdominales.

Abstract: BACKGROUND: Constipation, abdominal pain and bloating are highly prevalent in general population and they constitute a therapeutic challenge. Probiotics are effective in the management of these symptoms. OBJECTIVE: To investigate in daily clinical practice if the administration of a supplement food containing Bifidobacterium longum AW11 (5x109 FCU) and short chain fructo-oligosaccharides (Fos cc. Actilight 2.5g) can relieve constipation and functional bowel symptoms. PATIENTS AND METHOD: An open and observational study was done including patients with digestive symptoms of more than six months of evolution, without organic disease explaining their symptoms and who received treatment with the synbiotic, daily during eight weeks. Intensity and frequency of symptoms were assessed by a questionnaire and the characteristics of evacuations by Bristol's scale at baseline and after four and eight weeks of treatment. RESULTS: There were included 361 patients with digestive symptoms lasting 2.3±4.9 years; 96% had constipation, 79% fulfilled Rome III criteria for irritable bowel syndrome an 16% for functional constipation. Treatment with the synbiotic increased frequency of bowel movements per week from 3.8±3.3 to 5.9±3.0 at week 8 (p<0.00001). There was a significant improvement also for: complete spontaneous bowel movements, stool consistency (Bristol scale), straining, bloating, frequency of abdominal pain, malaise, and global wellness. Percentage of patients with complete satisfaction increased from 6% in the initial visit to 78% at the week 8. CONCLUSIONS: Daily ingestion of a synbiotic (B. longum and Fos cc.) is effective to relieve constipation, abdominal pain and bloating.

Desenvolvimento de sorvete simbiótico de açaí (Euterpe oleracea) com Lactobacillus rhamnosus GG e resistência do probiótico em um modelo de digestão gastrintestinal in vitro / Development of synbiotic açaí (Euterpe oleracea Mart. ) ice cream with Lactobacillus rhamnosus GG and probiotic resistance in an in vitro digestion gastrointestinal model

O objetivo do presente trabalho foi avaliar o efeito da adição de inulina (I-X1), concentrado proteico de soro de leite (WC-X2) e/ou isolado proteico de soro de leite (WI-X3) em sorvete simbiótico de açaí (Euterpe oleracea Mart.) sobre a viabilidade do probiótico L. rhamnosus GG e a sua sobrevivência frente às condições encontradas no trato gastrintestinal simuladas in vitro, bem como sobre as características tecnológicas e a aceitabilidade sensorial dos produtos resultantes, ao longo de seu armazenamento a -18°C por até 112 dias. Adicionalmente, os sorvetes de açaí foram caracterizados quanto à sua composição centesimal, ácidos graxos insaturados e potencial antioxidante. Por último, objetivou-se a otimização do sorvete simbiótico de açaí a partir dos parâmetros de dureza instrumental e fração de derretimento. Para este fim, foi empregado um delineamento experimental para misturas simples (centroid simplex) incluindo um ponto axial, utilizando diferentes proporções dos fatores X1, X2 e X3. No total, 9 formulações foram avaliadas por um período de até 112 dias de armazenamento congelado. As populações de L. rhamnosus GG permaneceram estáveis e entre 8 e 9 log ufc/g para todas as formulações e ao longo de todo o período de armazenamento. Entretanto, houve redução em, pelo menos, 5 ciclos logaritmos da população do probiótico, após 6 horas de simulação gastrintestinal em todos os períodos estudados, com uma recuperação de L. rhamnosus GG próxima a 4 log ufc/g. Apenas ao 7º dia de armazenamento, a resistência in vitro do probiótico nas formulações contendo inulina, WC e WI superou em até 0,93 log ufc/g a formulação controle. A composição de ácidos graxos revelou que o ácido oleico esteve em maior quantidade nas formulações (teor médio 46,47%), seguido do ácido palmitoleico (teor médio 42,12%). Os sorvetes apresentaram atividade antioxidante na faixa de 302,03 a 505,41 µmol TE/g. A maior atividade antioxidante foi observada para a formulação controle, seguida das formulações WC (4% de WC) e WI (4% de WI). As formulações WC (4% WC) e WI (4% WI) apresentaram os maiores valores de dureza, revelando que os fatores WC e WI exerceram forte influência na dureza dos produtos (p<0,05). As menores taxas de derretimento foram observadas nas formulações WI (4% de WI) e WC-WI (2% de WC; 2% de WI). Exceto para a formulação I-WC-WI (p<0,05), a presença de inulina nas demais formulações não alterou de forma significativa a velocidade de derretimento quando comprada à amostra controle. As formulações I-WI (2% de inulina; 2% de WI) e I-WC-WI (1,33% de inulina; 1,33% WC; 1,33 WI), apresentaram os maiores valores de overrun (37,95% e 39,18%, respectivamente). Os escores de aceitabilidade sensorial variaram de 5,83 a 7,63. Apenas as formulações WI (4% WI) e WC-WI (2% WC; 2% WI) aumentaram seus escores médios de aceitabilidade durante os 84 dias de armazenamento (p<0,05). De acordo com os modelos obtidos, WC foi o fator que mais contribuiu tanto para o aumento de dureza como para a velocidade de derretimento das formulações. A partir da otimização simultânea, considerando as respostas avaliadas (textura e fração de derretimento), é desejável que a formulação de sorvete simbiótico açaí seja produzida contendo 1,33% de inulina, 1,33% de WC e 1,33% de WI. Os resultados obtidos sugerem que a utilização dos três ingredientes (inulina, WC e WI) pode ser vantajosa no desenvolvimento de um sorvete probiótico de açaí, uma vez que a presença desses ingredientes contribuiu com o valor nutricional das formulações e também melhorou as características tecnológicas de overrun, derretimento e textura

The aimed of the present study was to evaluate the effect of inulin (I-X1), whey protein concentrate (WC-X2) and whey protein isolate (WI-X3) addition on the viability and in vitro survival of L. rhamnosus GG through in vitro simulated gastrointestinal tract (GIT), technological properties and sensory acceptance of symbiotic açai ice cream. Additionally, açai ice cream were characterized for their chemical composition, unsaturated fatty acids and antioxidant activity. Finally, we aimed to optimized the symbiotic açai ice cream using parameters of hardness and melting rate. For this purpose, an experimental design was used for simple mixture (simplex centroid) including an axial point, using different proportions of X1, X2 and X3, nine formulations of synbiotic açai ice cream were studied during frozen storage up to 112 days. A reduction of at least 5 log cycles of L. rhamnosus GG was observed in all formulations after 6 hours of the in vitro assays for all storage period evaluated. However, L. rhamnosus GG recovery was close to 4 log cfu/g for all formulations studied in evaluated periods. Nevertheless, on the 7th day of storage, the probiotic in vitro resistance in formulations supplemented with inulin, WC, and WI exceeded up to 0.93 log cfu/g the control formulation. The fatty acids composition showed that oleic acid was the highest fatty acid in synbiotic açai ice cream (mean content 46.47%), followed by palmitoleic acid (mean content 42.12%). The antioxidant activity of ice creams ranged from 302.03 to 505.41 µmol TE/g. Formulation C showed the highest antioxidant activity, followed by the formulations WC (WC 4%) and WI (WI 4%). Formulations WC (4% of WC) and WI (4% of WI) showed the highest hardness values, revealing that WC and WI exerted a strong influence on the product firmness. The lowest melting rate values were observed in formulation WI (4% of WI) and WC-WI (2% of WC, 2% of WI). However, the presence of inulin and WC showed strong influence on the melting rate of the ice creams, resulting in higher melting down of these products. I-WI and I-WC-WI formulations presented the highest overrun (37.95 and 39.18%, respectively). The sensory acceptability scores ranged from 5.83 to 7.63. WI and WC-WI formulations increased their mean acceptability scores significantly during 84 days of storage, whereas no significant differences were observed in acceptability throughout storage for the other formulations. According to the obtained models, WC was the factor that most contributed to increase both hardness and melting rate. From the simultaneous optimization, considering the responses evaluated (hardness and melting rate), it is desirable a symbiotic acai ice cream containing 1.33% of inulin, 1.33% of WC and 1.33% of WI. The results suggest that the use of the three ingredients (inulin, WC and WI) may be advantageous in the development of a synbiotic açai ice cream, since the presence of these ingredients contributed to the nutritional value of the formulations and also improved the technological characteristics of overrun, melting rate and texture

A randomized triple-masked controlled trial on the effects of synbiotics on inflammation markers in overweight children / Ensaio clínico controlado randomizado triplo-cego dos efeitos de simbióticos sobre marcadores de inflamação em crianças com sobrepeso

OBJECTIVE: the low degree of inflammation in obesity contributes to systemic metabolic dysfunction. Recent experimental studies proposed some effects of alteration in gut microbiota on inflammatory factors. This study aimed to assess the anti-inflammatory effects of a synbiotic supplement on inflammation markers in overweight and obese children and adolescents. METHODS: this randomized triple-masked controlled trial was conducted among 70 participants aged 6 to 18 years, with a body mass index (BMI) equal or higher than the 85th percentile. They were randomly assigned into two groups of equal number to receive synbiotic or placebo for eight weeks. RESULTS: fifty-six of 70 participants (80%) completed the study. Compared with the placebo group, the synbiotic group had significant decrease in mean values of tumor necrosis-α and interleukin-6, with significant increase in adiponectin; these changes were no longer significant after adjustment for BMI. There was no significant change in the mean values of high-sensitive C-reactive protein. CONCLUSION: the present findings suggest the positive influence of synbiotic supplementation on inflammation factors, which are dependent to its effect on weight reduction in overweight and obese children. .

OBJETIVO: o baixo grau de inflamação na obesidade contribui para disfunção metabólica sistêmica. Estudos experimentais recentes propuseram alguns efeitos de alteração na microbiota intestinal sobre fatores inflamatórios. O objetivo deste estudo foi avaliar os efeitos anti-inflamatórios de um suplemento simbiótico sobre marcadores de inflamação em crianças e adolescentes com sobrepeso e obesos. MÉTODOS: este ensaio clínico controlado randomizado triplo-cego foi conduzido entre 70 participantes com idade entre seis e 18 anos, com índice de massa corporal (IMC) igual ou acima do 85º percentil. Eles foram aleatoriamente divididos em dois grupos de igual número de participantes para receber simbiótico ou placebo por oito semanas. RESULTADOS: no todo, 56 de 70 participantes (80%) concluíram o estudo. Em comparação ao grupo placebo, o grupo simbiótico teve redução significativa nos valores médios de necrose tumoral-α e interleucina-6, com aumento significativo na adiponectina; essas alterações não eram mais expressivas após o ajuste do IMC. Não houve alteração importante nos valores médios da proteína C-reativa altamente sensível. CONCLUSÃO: nossas conclusões sugerem a influência positiva da suplementação simbiótica sobre fatores inflamatórios, dependente de seu efeito sobre a redução de peso em crianças com sobrepeso e obesas. .

Desenvolvimento de margarina probiótica e simbiótica: viabilidade do probiótico no produto e resistência in vitro / Development of probiotic and synbiotic margarine: viability of probiotic in the product and in vitro resistance

O presente trabalho teve como objetivo verificar a viabilidade da cepa probiótica Bifidobacterium animalis subsp. lactis Bb-12 incorporado em margarina, suplementada com inulina, concentrado protéico de soro (WPC) e concentrado de caseína (CMP), bem como avaliar as características do produto e a resistência do probiótico às condições simuladas do trato gastrintestinal humano. Foram produzidos 7 diferentes tipos de margarinas de mesa (60% de lipídios: 60 % de óleo de palma + 40% de óleo de canola), empregando-se um modelo de mistura, onde inulina, WPC e CMP foram as variáveis estudadas. Uma formulação controle foi produzida (M8), sem adição desses ingredientes. A utilização da mistura do óleo de palma com óleo de canola favoreceu nutricionalmente as formulações, fornecendo produtos contendo ácidos graxos essenciais em sua composição e ausência de ácidos graxos trans. As formulações M1 a M7, exceto a formulação M2 após o 21º dia de armazenamento, apresentaram populações satisfatórias de Bb-12 para um alimento probiótico, com populações acima de 6 log UFC/g durante 35 dias de armazenamento. Margarinas suplementadas com inulina apresentaram populações satisfatórias durante todo o armazenamento, atingindo populações de 8,01 log UFC/g ao 35º dia (M1). Além disso, M3 e M6, revelaram populações de Bb-12 de 6,87 log UFC/g e 7,27 log UFC/g (dia 35), respectivamente. Por outro lado, M8 não foi caracterizada como margarina probiótica, uma vez que apresentou populações abaixo de 6 log UFC/g, já ao 1º dia de armazenamento. Embora WPC seja utilizado em pesquisas para aumentar a viabilidade de probióticos em alimentos, a suplementação de margarina com WPC sem inulina ou CMP não resultou em populações satisfatórias de Bb-12, apresentando decréscimo de 7,82 (dia 1) para 4,64 log UFC/g (M2, dia 35) (p<0,05). Durante todo o ensaio de resistência in vitro, Bb-12 apresentou sobrevivência significativamente superior (p<0,05) em M1 e revelou populações acima de 6 log UFC/g após 6h de...

This study aimed to determine the viability of probiotic Bifidobacterium animalis subsp. lactis Bb-12 incorporated in margarine, with inulin, whey protein concentrate (WPC) and caseinomacropeptide (CMP) supplementation. In addition, the in vitro resistance of Bb-12 incorporated in margarine and related properties were evaluated. Seven margarine-making trials (60% of fat: 60% of palm oil +40% canola oil) were produced, using a mixture model, where inulin, WPC and CMP were the variables studied. Also, a control formulation without these ingredients was manufactured. The use of blending palm oil with canola oil improved the margarine formulations nutritionally, providing products containing essential fatty acids in its composition and absence of trans fatty acids. The formulations M1 to M7, except M2 after 21 days of storage, revealed satisfactory Bb-12 populations for a probiotic food, with counts above 6 log CFU/g during 35 days of storage at 5±1ºC. Margarines supplemented with inulin presented suitable Bb-12 populations throughout the whole storage period, reaching up to 8 log CFU/g by the end of storage (M1). Also, M3 and M6, revealed Bb-12 populations of 6.87 log CFU/g and of 7.27 log CFU/g (day 35), respectively. In contrast, M8 was not characterized as probiotic margarine, since it showed Bb-12 populations below 6 log CFU/g on day 1. Even though whey protein is largely employed in probiotic foods, margarine supplementation with WPC without inulin or CMP did not lead to Bb-12 satisfactory populations, decreasing from 7.82 (day 1) to 4.64 log CFU/g (M2, day 35) (p<0.05). During the whole in vitro assays, Bb-12 survived significantly better (p<0.05) in M1 and revealed populations above 6 log CFU/g after 6h even after 28 days. M2 populations decreased drastically during the in vitro assays for all storage period tested (reduction of 5 log CFU/g after 2h of in vitro assays on day 7 and populations of 2.8 log CFU/g after 6h). For the other formulations, Bb-12...